Last reviewed · How we verify
Insulin glulisine, Insulin glargine
At a glance
| Generic name | Insulin glulisine, Insulin glargine |
|---|---|
| Sponsor | HaEmek Medical Center, Israel |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Insulin Glulisine (GP40321) Compared to Insulin Glulisine (Apidra® SoloStar®) in Type 1 Diabetes Mellitus Patients (PHASE3)
- Afrezza® INHALE-1 Study in Pediatrics (PHASE3)
- Degludec Glargine U300 Hospital Study (NA)
- Closed Loop From Onset in Type 1 Diabetes (NA)
- Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes (PHASE3)
- FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR) (PHASE4)
- Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy (PHASE4)
- Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |